Mounjaro Wegovy Weight Loss Weight Management

Jun 22, 2026
14 MIN READ

Is Wegovy Better Than Mounjaro for Weight Loss?

Wegovy and Mounjaro represent two distinct approaches to GLP-1 therapy for weight management. Understanding their mechanisms, clinical outcomes, and cost differences helps you choose the right treatment for your body and budget.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 22, 2026
14 MIN READ

is wegovy better than mounjaro for weight loss? — PlexusDx GLP-1 education

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide (Wegovy) and tirzepatide (Mounjaro) are both glucagon-like peptide-1 therapies proven to reduce body weight, but they work through different biological pathways. Clinical data shows tirzepatide produces greater weight loss than semaglutide in head-to-head trials, with some patients achieving reductions exceeding 20% of baseline body weight.

How Semaglutide and Tirzepatide Work Differently

Semaglutide is a single-action GLP-1 receptor agonist, meaning it activates only one appetite-control pathway in your brain and gut. This mechanism reduces hunger signals, slows stomach emptying, and increases feelings of fullness after smaller meals. Semaglutide has been used for diabetes management since 2009 and was adapted for weight loss as Wegovy in 2021.

Tirzepatide is a dual-action compound that activates both GLP-1 and GIP receptors simultaneously. By targeting two distinct appetite pathways instead of one, tirzepatide produces stronger suppression of hunger and greater metabolic effects on how your body processes nutrients. This dual mechanism explains why tirzepatide typically delivers superior weight loss results in comparative studies.

Clinical Weight Loss Results: Tirzepatide Outperforms Semaglutide

The SURMOUNT clinical trial program, which evaluated tirzepatide across multiple studies, demonstrated average weight reductions of 20-22% of baseline body weight at the highest dose. In contrast, Wegovy trials (STEP program) showed average weight loss of 14-17% at equivalent therapeutic doses. Both medications require ongoing use to maintain weight loss, as weight typically returns within months of stopping treatment.

Head-to-head comparisons reveal that tirzepatide achieves clinically meaningful weight loss in a larger percentage of patients and tends to produce results more rapidly than semaglutide. Individual response varies significantly based on genetics, lifestyle, and metabolic factors—which is why genetic testing can help predict which compound aligns with your peptide pathways.

Side Effect Profiles and Tolerability Differences

Both semaglutide and tirzepatide cause similar gastrointestinal side effects, including nausea, vomiting, constipation, and diarrhea, particularly during dose escalation. These effects typically diminish within 2-4 weeks as your body adapts. Semaglutide generally has a slightly gentler tolerability profile in early weeks, while tirzepatide's stronger dual action may cause more pronounced initial nausea in some patients.

Serious side effects are rare with both medications when used as directed under medical supervision. Both carry warnings about pancreatitis history and thyroid concerns, and neither should be used if you have a personal or family history of medullary thyroid cancer. Most patients find gastrointestinal side effects manageable and temporary compared to the sustained appetite suppression benefits.

PlexusDx Compounded Options and Personalized Pricing

PlexusDx offers compounded semaglutide and tirzepatide injections from licensed 503A pharmacies at transparent, flat monthly pricing—$149/month for compounded semaglutide injection and $249/month for compounded tirzepatide injection. Your dose may need to go up as you progress through a titration schedule, but your price remains flat regardless of dose strength. Both medications are available without insurance, with no membership fees, and are HSA/FSA eligible.

For patients seeking maximum synergy between both compounds, PlexusDx offers GLP-Squared Injection (a dual-compound tirzepatide plus semaglutide formulation) starting at $249/month. PlexusDx also offers the Precision Peptide Genetic Test ($99 add-on after your first month) to map your individual peptide pathways across 14 biological systems and 49 distinct peptides, helping predict which medication and dose protocol will deliver the strongest response for your unique genetics.

Oral vs. Injectable Formulations and Administration

Wegovy is available only as a once-weekly subcutaneous injection, while compounded semaglutide from PlexusDx offers both injection and oral tablet options ($249/month for oral). Similarly, Mounjaro is a once-weekly injection, but PlexusDx provides compounded tirzepatide as both injection and oral formulations ($279/month for oral tirzepatide). Oral formulations offer convenience for patients who prefer to avoid injections, though absorption rates differ slightly between routes.

Injectable medications generally reach therapeutic levels more reliably than oral tablets, which is why many patients achieve faster, more predictable weight loss with injections. PlexusDx microdose GLP-1 protocol ($129/month) offers another option for patients seeking lower starting doses or those with injection sensitivity. Your PlexusDx medical team helps match the administration route and formulation strength to your preferences and metabolic goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will I lose more weight with tirzepatide than semaglutide?

Clinical trials indicate tirzepatide produces 5-8% greater average weight loss than semaglutide, with many patients on tirzepatide achieving 20%+ reductions. However, individual responses vary based on genetics, diet, and exercise. PlexusDx Precision Peptide Genetic Testing can identify which compound aligns best with your GLP1R and GIPR genetic variants.

Is compounded tirzepatide from PlexusDx the same as brand-name Mounjaro?

PlexusDx tirzepatide is manufactured by licensed 503A compounding pharmacies using the same active pharmaceutical ingredient as Mounjaro. It is not FDA-approved as a brand medication, but it delivers identical therapeutic effects at a significantly lower cost ($249/month flat). Both versions require medical supervision and regular dose adjustments.

Can I switch from Wegovy to Mounjaro mid-treatment?

Yes, switching between semaglutide and tirzepatide is medically feasible under supervision, though your dose will need to be adjusted because tirzepatide's dual action is more potent. PlexusDx medical providers can manage this transition safely and monitor your response to ensure optimal weight loss without excessive side effects.

Which medication causes fewer side effects, Wegovy or Mounjaro?

Both cause similar gastrointestinal side effects like nausea and constipation, especially during the first 2-4 weeks. Semaglutide may feel slightly gentler initially, while tirzepatide's stronger dual action occasionally produces more pronounced early nausea. Side effects typically resolve as your body adapts, and most patients tolerate them well compared to the appetite-suppression benefits.

How does the Precision Peptide Genetic Test help me choose between semaglutide and tirzepatide?

PlexusDx Precision Peptide Genetic Test ($99) analyzes your GLP1R and GIPR gene variants alongside 47 other peptide pathways to predict how efficiently your body will respond to each medication. Patients with favorable GIPR variants often achieve superior results with tirzepatide's dual-action approach, while those with specific GLP1R profiles may respond optimally to semaglutide alone.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves